20 September 1999 00:00 [Source: ICB Americas]
Biomira Inc., revising its collaboration with Chiron Corp., has signed an option agreement with Chiron permitting Biomira to reacquire all rights held by Chiron in relation to Theratope vaccine. Both companies plan to bring in a third party to participate in the development and commercialization of Theratope. To facilitate this, Chiron has agreed to sell its rights and obligations for Theratope back to Biomira.For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.